TELA Bio, Inc. 8K

TELA Bio announced the immediate departure of its COO/CFO and a restructuring plan including a 20% headcount reduction to cut annual operating expenses by $17 million and extend its cash runway into 2028.

On August 31, 2026, TELA Bio, Inc. announced that its Chief Operating Officer and Chief Financial Officer, Roberto Cuca, stepped down from his role effective immediately, and concurrently unveiled a strategic cost reduction initiative expected to lower annual operating expenses by approximately $17.0 million, or 18%, driven by a roughly 20% reduction in headcount and streamlining of external resources. The company stated that the restructuring is designed to preserve investment in core growth priorities and product innovation while extending its cash runway into 2028, and it expects to incur a one-time restructuring charge of about $1.5 million in the third quarter of 2026 related primarily to severance and other employee costs, with further details to be provided on its third quarter 2026 earnings call planned for early November.

Filing Facts

CIK

1561921

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-103548

Alert Tier

7